HUT68957A - Azanorbornane derivatives and pharmaceutical compositions comprising them as effective substance - Google Patents

Azanorbornane derivatives and pharmaceutical compositions comprising them as effective substance Download PDF

Info

Publication number
HUT68957A
HUT68957A HU9303666A HU9303666A HUT68957A HU T68957 A HUT68957 A HU T68957A HU 9303666 A HU9303666 A HU 9303666A HU 9303666 A HU9303666 A HU 9303666A HU T68957 A HUT68957 A HU T68957A
Authority
HU
Hungary
Prior art keywords
alkyl
phenyl
amino
diphenylmethyl
pyrrolidine
Prior art date
Application number
HU9303666A
Other languages
English (en)
Hungarian (hu)
Other versions
HU9303666D0 (en
Inventor
Brian Thomas O'nell
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HU9303666D0 publication Critical patent/HU9303666D0/hu
Publication of HUT68957A publication Critical patent/HUT68957A/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Ink Jet (AREA)
  • Fertilizers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HU9303666A 1991-06-21 1992-06-11 Azanorbornane derivatives and pharmaceutical compositions comprising them as effective substance HUT68957A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71988491A 1991-06-21 1991-06-21

Publications (2)

Publication Number Publication Date
HU9303666D0 HU9303666D0 (en) 1994-04-28
HUT68957A true HUT68957A (en) 1995-08-28

Family

ID=24891766

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9303666A HUT68957A (en) 1991-06-21 1992-06-11 Azanorbornane derivatives and pharmaceutical compositions comprising them as effective substance

Country Status (18)

Country Link
US (1) US5604252A (en:Method)
EP (1) EP0591333B1 (en:Method)
KR (1) KR940701384A (en:Method)
AT (1) ATE149497T1 (en:Method)
AU (1) AU2188992A (en:Method)
CA (1) CA2111335A1 (en:Method)
DE (1) DE69217945T2 (en:Method)
DK (1) DK0591333T3 (en:Method)
FI (1) FI935726L (en:Method)
HU (1) HUT68957A (en:Method)
IE (1) IE921987A1 (en:Method)
IL (1) IL102208A0 (en:Method)
MX (1) MX9203053A (en:Method)
NO (1) NO934727D0 (en:Method)
PT (1) PT100607A (en:Method)
TW (1) TW202432B (en:Method)
WO (1) WO1993000330A2 (en:Method)
ZA (1) ZA924527B (en:Method)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5364943A (en) * 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
DK0533280T4 (da) 1991-09-20 2005-02-28 Glaxo Group Ltd Ny medicinsk anvendelse af tachykininantagonister
US5498614A (en) * 1992-05-18 1996-03-12 Pfizer Inc. Bridged aza-bicyclic derivatives as substance P antagonist
WO1994003445A1 (en) * 1992-08-04 1994-02-17 Pfizer Inc. 3-benzylamino-2-phenyl-piperidine derivatives as substance p receptor antagonists
AU4224993A (en) * 1992-08-19 1994-03-15 Pfizer Inc. Substituted benzylamino nitrogen containing non-aromatic heterocycles
PT675886E (pt) * 1992-12-10 2000-12-29 Pfizer Heterociclos nao aromaticos com substituintes aminometileno e sua utilizacao como antagonistas da substancia p
FR2700472B1 (fr) 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5635510A (en) * 1993-05-06 1997-06-03 Merrell Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (en) * 1993-11-17 1995-10-11 Pfizer Substance P antagonists for the treatment or prevention of sunburn.
EP0659409A3 (en) * 1993-11-23 1995-08-09 Pfizer Substance P antagonists for the inhibition of angiogenesis.
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
MX9701305A (es) 1994-08-25 1998-05-31 Merrell Pharma Inc Piperidinas sustituidas novedosas utiles para el tratamiento de enfermedades alergicas.
FR2728169A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2728165A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
ATE277021T1 (de) * 1995-04-13 2004-10-15 Aventis Pharma Inc Neue substituierte piperazinderivate mit tachykininrezeptor-antagonistischer wirkung
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US5998439A (en) 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
MXPA02004330A (es) 1999-11-03 2004-07-30 Albany Molecular Res Inc Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina..
HUP0300413A2 (hu) * 2000-04-10 2003-06-28 Pfizer Products Inc. Amidcsoportot viselő benzolgyűrűs csoporttal helyettesített piperidint tartalmazó és rokonszerkezetű vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
US7119207B2 (en) * 2000-04-10 2006-10-10 Pfizer Inc Benzoamide piperidine containing compounds and related compounds
US7084152B2 (en) 2000-07-11 2006-08-01 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
WO2006020049A2 (en) 2004-07-15 2006-02-23 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
BRPI0516602A (pt) * 2004-10-18 2008-09-16 Lilly Co Eli composto, e, composição farmacêutica
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
GEP20125566B (en) 2005-07-15 2012-07-10 Amr Technology Inc Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2770486C (en) 2006-09-22 2014-07-15 Merck Sharp & Dohme Corp. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
EP2145884B1 (en) 2007-04-02 2014-08-06 Msd K.K. Indoledione derivative
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CA2717509A1 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AU2010247735B2 (en) 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
MX2011011901A (es) 2009-05-12 2012-01-20 Albany Molecular Res Inc Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas.
KR101830447B1 (ko) 2009-05-12 2018-02-20 알바니 몰레큘라 리써치, 인크. 7-(［1,2,4］트리아졸로［1,5-α］피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도
CN104945382B (zh) 2009-10-14 2020-02-07 默沙东公司 提高p53活性的取代的哌啶和其用途
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
EP3587574B1 (en) 2010-08-17 2022-03-16 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
EP3327125B1 (en) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
CA2831730A1 (en) 2011-04-21 2012-10-26 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3453762B1 (en) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
KR20150060724A (ko) 2012-09-28 2015-06-03 머크 샤프 앤드 돔 코포레이션 Erk 억제제인 신규 화합물
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
DK2925888T3 (en) 2012-11-28 2017-12-18 Merck Sharp & Dohme COMPOSITIONS AND METHODS OF CANCER TREATMENT
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833355A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
WO2020254552A2 (en) * 2019-06-19 2020-12-24 Grünenthal GmbH Substituted pyrrolidine amides v

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823605D0 (en) * 1988-10-07 1988-11-16 Merck Sharp & Dohme Therapeutic agents
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
UA41251C2 (uk) * 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
WO1991018899A1 (en) * 1990-06-01 1991-12-12 Pfizer Inc. 3-amino-2-aryl quinuclidines, process for their preparation and pharmaceutical compositions containing them
DK0540526T3 (da) * 1990-07-23 1995-04-18 Pfizer Quinuclidinderivater
DK0550635T3 (da) * 1990-09-28 1995-09-04 Pfizer Cykliske forbindelser med kondeserede ringe, som er analoger til nitrogenholdige ikke-aromatiske het erocykliske forbindelser

Also Published As

Publication number Publication date
CA2111335A1 (en) 1993-01-07
HU9303666D0 (en) 1994-04-28
FI935726A7 (fi) 1993-12-20
DK0591333T3 (da) 1997-05-20
WO1993000330A2 (en) 1993-01-07
IL102208A0 (en) 1993-01-14
DE69217945T2 (de) 1997-06-12
NO934727L (no) 1993-12-20
KR940701384A (ko) 1994-05-28
NO934727D0 (no) 1993-12-20
TW202432B (en:Method) 1993-03-21
ZA924527B (en) 1993-12-20
US5604252A (en) 1997-02-18
IE921987A1 (en) 1992-12-30
AU2188992A (en) 1993-01-25
PT100607A (pt) 1993-08-31
DE69217945D1 (de) 1997-04-10
WO1993000330A3 (en) 1993-03-04
MX9203053A (es) 1992-12-01
FI935726A0 (fi) 1993-12-20
EP0591333B1 (en) 1997-03-05
EP0591333A1 (en) 1994-04-13
ATE149497T1 (de) 1997-03-15
FI935726L (fi) 1993-12-20

Similar Documents

Publication Publication Date Title
HUT68957A (en) Azanorbornane derivatives and pharmaceutical compositions comprising them as effective substance
RU2083574C1 (ru) Полициклические аминосодержащие соединения или их соли, их оптически чистые изомеры, способ получения полициклических аминосодержащих соединений, циклические аминосодержащие соединения или их соли, их оптически чистые изомеры и фармацевтическая композиция, обладающая антагонистической активностью к рецепторам нейрокинина
US5869499A (en) Benzyloxyquinuclidines as substance P antagonists
KR100238343B1 (ko) 인간 nk3 수용기의 선택적 길항제인 화합물, 및 의약품 및 진단기구로서의 그의 용도
CA2528652A1 (en) Nk1 antagonist
DE69221919T2 (de) Piperidin-Derivate
BRPI0215158B1 (pt) Compounds derived from pyrrolidine and piperidine as antagonists of nk1, pharmaceutical composition and use thereof
PL164203B1 (pl) Sposób wytwarzania nowych pochodnych 3-amlnopiperydyny PL PL PL PL PL PL PL
CZ287272B6 (en) Quaternary basic amide, process of its preparation and pharmaceutical composition in which the amide is comprised
CZ299294A3 (en) Process for preparing 3,4,4-trisubstituted derivative of piperidyl-n-alkylcarboxylate, a pharmaceutical composition containing thereof and process for preparing intermediates therefor
JPH06501267A (ja) 窒素含有非芳香族複素環の縮合環類似体
TWI764467B (zh) 具有khk抑制作用的化合物
HUT65771A (en) Process for producing substituted 3-amino-quinuclidine derivatives and pharmaceutical compositions containing them
JP2002138088A (ja) 置換環式化合物
JP2008531677A (ja) ペプチド様化合物及び生物活性誘導体の製造
US20150018340A1 (en) Pipecolate-diketoamides for treatment of psychiatric disorders
TW202304864A (zh) 1,3-取代的環丁基衍生物及其用途
EP0700382A1 (fr) Nouveaux amides n-arylaliphatiques-n-alkyl-fonctionnalises, procede pour leur preparation et compositions pharmaceutiques en contenant
US6083943A (en) Substituted azaheterocyclecarboxylic acid
JPH0788356B2 (ja) アザノルボルナン誘導体
AU605434B2 (en) Amino-substituted bridged azabicyclic quinolone carboxylic acids and esters
NO312244B1 (no) 1-azobicyklo(2.2.1)heptan-derivater, fremgangsmåte for fremstilling derav og farmasöytiske blandinger
FR2717477A1 (fr) Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
JPH1081684A (ja) 置換３−アミノキヌクリジン薬剤組成物
JP2012517412A (ja) Ｎ−［（６−アザビシクロ［３．２．１］オクト−１−イル）−アリール−メチル］−ベンズアミド誘導体、これらの調製およびこれらの治療的使用

Legal Events

Date Code Title Description
DFD9 Temporary protection cancelled due to non-payment of fee